References
- Allen, G. C., Rosenberg, H., Fletcher, J. E. (1990). Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility. Anesthesiology, 72(4), 619-622.
- Bonciu, M., Chapelle, A., Delpech, H., Depret, T., Krivosic-Horber, R., Aime, M. R. (2007). Minor increase of endtidal CO2 during sevoflurane induced malignant hyperthermia. Pediatric Anesthesia, 17, 180-182.
- Cohen, I. T., Kaplan, R. (2006). Repeat episodes of severe muscle rigidity in a child receiving sevoflurane. Paediatric Anaesthesia. 16(10), 1077-1079.
- Denbrough, M. (1998). Malignant hyperthermia. Lancet, 352, 1131-1136.
- Denborough, M. A., Lowell, R. H. (1960) Anaesthetic deaths in a family (letter). Lancet, 2, 45.
- Greenberg, D. A. (1999). Muscle & Nerve, 22(10), 1341-1349.
- Halsall, P. J., Cain, P. A., Ellis, F. R. (1979). Retrospective analysis of anaesthetics received by patients before susceptibility to malignant hyperpyrexia was recognised. Brit. J. Anaesth., 51, 949-954.
- Islander, G., Ranklev-Twetman, E. (1995). Evaluation of anaesthesias in malignant hyperthermia negative patients. Acta Anaesthesiol. Scand, 39(6), 819-821.
- Krause, T., Gerbershagen, M. U., Fiege, M., Weisshorn, R., Wappler, F. (2004). Dantrolene—a review of its pharmacology, therapeutic use and new developments. Anaesthesia, 59(4), 364-373.
- Larach, M. G., Brandom, B. W., Allen, G. C., Gronert, G. A., Lehman, E. B. (2008). Cardiac arrests and deaths associated with malignant hyperthermia in north america from 1987 to 2006: A report from the north american malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesthesiology, 108(4), 603-611.
- Ording, H., Hedengran, A. M., Skovgaard, L. T. (1991). Evaluation of 119 anaesthetics received after investigation for susceptibility to malignant hyperthermia. Acta Anaesthesiol. Scand., 35(8), 711-716.
- Ording, H., Brancadoro, V., Cozzolino, S., Ellis, F. R., Glauber, V., Gonano, E. F., Halsall, P. J., Hartung, E., Heffron, J. J., Heytens, L., Kozak-Ribbens, G., Kress, H., Krivosic-Horber, R., Lehmann-Horn, F., Mortier, W., Nivoche, Y., Ranklev-Twetman, E., Sigurdsson, S., Snoeck, M., Stieglitz, P., Tegazzin, V., Urwyler, A., Wappler, F. (1997). In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol. Scand., 41(8), 955-966.
- Rosenberg, H., Davis, M., James, D., Pollock, N., Stwell, K. (2007). Malignant hyperthermia. Orphanet J. Rare Dis., 24, 2-21.
- Scala, D., Di Martino, A., Cozzolino, S., Mancini, A., Bracco, A., Andria, B., Tammaro, A., Savoia, G. (2006). Follow-up of patients tested for malignant hyperthermia susceptibility. Eur. J. Anaesthesiol., 23(9), 801-805.
- Tammaro, A., Bracco, A., Cozzolino, S., Esposito, M., Di Martino, A., Savoia, G., Zeuli, L., Piluso, G., Aurino, S., Nigro, V. (2003). Scanning for mutations of the ryanodine receptor (RYR1) gene by denaturing HPLC: Detection of three novel malignant hyperthermia alleles. Clin. Chem., 49(5), 761-768.
- Urwyler, A., Deufel, T., McCarthy, T., West, S. (2001) Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. European Malignant Hyperthermia Group. Brit. J. Anaesth., 86(2), 283-287.
- Wappler, F. (2001). Malignant hyperthermia. Eur. J. Anaesthesiol., 18, 632-652.
- Wedel, D. J. (1992). Malignant hyperthermia and neuromuscular disease. Neuromuscular Disorders, 2(3), 157-164.
- Wehner, M., Rueffert, H., Koenig, F., Neuhaus, J., Olthoff, D. (2002). Increased sensitivity to 4-chloro-m-cresol and caffeine in primary myotubes from malignant hyperthermia susceptible individuals carrying the ryanodine receptor 1 Thr2206Met (C6617T) mutation. Clin. Genet., 62(2), 135-146.